Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
39
ANRO Quote, Financials, Valuation and Earnings
Last price:
$13.43
Seasonality move
:
-30.43%
Day range:
$12.95 - $13.71
52-week range:
$1.60 - $16.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.74x
Volume:
206.6K
Avg. volume:
460.4K
1-year change:
244.36%
Market cap:
$417.2M
Revenue:
--
EPS (TTM):
-$2.30
Analysts' Opinion
-
Consensus RatingAlto Neuroscience, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.25, Alto Neuroscience, Inc. has an estimated upside of 117.8% from its current price of $13.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $13.43.
Fair Value
-
According to the consensus of 10 analysts, Alto Neuroscience, Inc. has 117.8% upside to fair value with a price target of $29.25 per share.
ANRO vs. S&P 500
-
Over the past 5 trading days, Alto Neuroscience, Inc. has underperformed the S&P 500 by -3.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Alto Neuroscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alto Neuroscience, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Alto Neuroscience, Inc. reported revenues of --.
Earnings Growth
-
Alto Neuroscience, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Alto Neuroscience, Inc. reported earnings per share of -$0.52.
Enterprise value:
306.9M
EV / Invested capital:
2.21x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.74x
EV / Free cash flow:
-5.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$605K
Return On Assets:
-36.8%
Net Income Margin (TTM):
--
Return On Equity:
-45.08%
Return On Invested Capital:
-38.64%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -$489K | -$605K | -$200K | -$164K | |
| Operating Income | -$34.1M | -$63.4M | -$66.3M | -$18.9M | -$15M | |
| EBITDA | -$31.4M | -$62.9M | -$65.7M | -$18.7M | -$14.8M | |
| Diluted EPS | -$1.85 | -$2.13 | -$2.30 | -$0.62 | -$0.52 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $183.5M | $139.4M | |
| Total Assets | -- | -- | -- | $191.6M | $147M | |
| Current Liabilities | -- | -- | -- | $14M | $9M | |
| Total Liabilities | -- | -- | -- | $26.6M | $35.4M | |
| Total Equity | -- | -- | -- | $165.1M | $111.6M | |
| Total Debt | -- | -- | -- | $16.1M | $26.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$45.9M | -$53.3M | -$11.7M | -$9.9M | |
| Cash From Investing | -- | -$1.9M | -$530K | -$1M | -- | |
| Cash From Financing | -- | $178.8M | $9.9M | $1.3M | $153K | |
| Free Cash Flow | -- | -$47.8M | -$53.8M | -$12.7M | -$9.9M | |
ANRO
Sector
Market Cap
$417.2M
$28.5M
Price % of 52-Week High
81.44%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-3.06%
-1.33%
1-Year Price Total Return
244.36%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.35
200-day SMA
Buy
Level
$4.75
Bollinger Bands (100)
Buy
Level
2.61 - 11.31
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Buy
Level
$13.35
Relative Strength Index (RSI14)
Buy
Level
55.72
ADX Line
Buy
Level
22.98
Williams %R
Neutral
Level
-77.5665
50-day SMA
Buy
Level
$10.45
MACD (12, 26)
Buy
Level
0.72
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
76.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3363)
Sell
CA Score
(Annual)
Level (-3.7165)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.1223)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Stock Forecast FAQ
In the current month, ANRO has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ANRO average analyst price target in the past 3 months is $29.25.
-
Where Will Alto Neuroscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alto Neuroscience, Inc. share price will rise to $29.25 per share over the next 12 months.
-
What Do Analysts Say About Alto Neuroscience, Inc.?
Analysts are divided on their view about Alto Neuroscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alto Neuroscience, Inc. is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Alto Neuroscience, Inc.'s Price Target?
The price target for Alto Neuroscience, Inc. over the next 1-year time period is forecast to be $29.25 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ANRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alto Neuroscience, Inc. is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANRO?
You can purchase shares of Alto Neuroscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alto Neuroscience, Inc. shares.
-
What Is The Alto Neuroscience, Inc. Share Price Today?
Alto Neuroscience, Inc. was last trading at $13.43 per share. This represents the most recent stock quote for Alto Neuroscience, Inc.. Yesterday, Alto Neuroscience, Inc. closed at $13.43 per share.
-
How To Buy Alto Neuroscience, Inc. Stock Online?
In order to purchase Alto Neuroscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ANRO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANRO
Sector
P/E ratio
--
23.75x
PEG ratio
-0.74x
-0.01x
P/B ratio
3.74x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
ANRO
Sector
Revenue growth
--
4.85%
Earnings growth
15.93%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.64
-$0.20
Profitability
ANRO
Sector
Profitability FY 2024
-$502K
$3.6M
Return on invested capital
-38.64%
-30.98%
Return on assets
-36.8%
-27.62%
Return on equity
-45.08%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
ANRO
Sector
Total cash
$137.8M
$27.2M
Short term investments
--
$25.7M
Total assets
$177.5M
$79.7M
Long term debt
$26.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
